loading...| Preferred Name |
ritonavir |
|
| Synonyms |
RIT |
|
| Definitions |
A synthetic aromatic derivative with antiviral properties. Ritonavir is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases, thereby preventing the cleavage of Gag-Pol polyproteins and resulting in the production of noninfectious viral particles. This agent is more active against HIV-1. Because ritonavir targets the HIV replication cycle after translation and before assembly, it is active in chronically infected cells that generally are not affected by nucleoside reverse transcriptase inhibitors. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1609" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1609" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000042665 |
|
| altLabel |
RIT Norvir |
|
| Component of | ||
| cui |
C0678152 C0292818 |
|
| definition |
A synthetic aromatic derivative with antiviral properties. Ritonavir is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases, thereby preventing the cleavage of Gag-Pol polyproteins and resulting in the production of noninfectious viral particles. This agent is more active against HIV-1. Because ritonavir targets the HIV replication cycle after translation and before assembly, it is active in chronically infected cells that generally are not affected by nucleoside reverse transcriptase inhibitors. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1609" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1609" NCI Thesaurus) |
|
| Legacy PDQ ID |
6427 |
|
| LT |
TRD |
|
| NCI ID |
C1609 |
|
| notation |
CDR0000042665 |
|
| NSC Code |
693184 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
ritonavir |
|
| tui |
T109 T121 |